AN UNBIASED VIEW OF LDN-27219 AS A CANCER DRUG CANDIDATE

One particularly attention-grabbing compound is LDN-27219. When most tTG inhibitors are designed to bind to your protein crosslinking active site, LDN-27219 in its place binds to your nucleotide binding pocket in the enzyme whilst it is actually in its closed-condition conformation, and stabilizes that conformation to stop crosslinking activity.sev